Bristol-Myers Squibb
BMY
$0.00 (0.00%)
1D
1W
3M
1Y
5Y
ALL
Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. Its pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics and government agencies.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
The Motley Fool • 2 days ago • BMY
Do These 3 Healthcare Stocks Need a Checkup?
Zacks Investment Research • 2 days ago • BMY
Will Breyanzi's Label Expansion Boost BMY's CAR T Cell Therapy Sales?
Business Wire • 2 days ago • BMY
Bristol Myers Squibb's Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)
Seeking Alpha • 2 days ago • BMY
Bristol-Myers Squibb Company (BMY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Zacks Investment Research • 3 days ago • BMY
BMY Gains on News of Continuation of Alzheimer's Disease Study
Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.